Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs
AssigneesOgd2 Pharma, Nantes Universite, Centre National de la Recherche Scientifique (CNRS), Institut National De La Sante Et De La Recherche Medicale (Inserm), Institut De Cancerologie De L'ouest
InventorsStéphane BIRKLE, Julien FLEURENCE, Sébastien FARAJ, Jean-Marc LE DOUSSAL, Denis COCHONNEAU, Mickaël TERME, Brigitte ASSOULINE
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
Claims16
An in vitro/ex vivo method of identifying synergistic combination of (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons and, (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside, comprising the steps of:
- a) incubating primary tumor cells or cancer cell lines cells expressing the O-acetylated form of GD2 ganglioside in vitro with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons and, (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside, and
- b) measuring the CI50 index according to the method as disclosed by Chou and Talalay, wherein a CI50 below 1 is indicative of synergism.
A kit suitable for treating cancer expressing OAcGD2 ganglioside comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside, and optionally (iii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.